// App-Quantinova.ai

: Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).

Researchers

Presenter

  • Jonathan E. Rosenberg

Principal Investigators

  • Jingsong Zhang

  • David C. Smith

  • Joseph D. Ruether

  • Thomas W. Flaig

  • Joaquina Celebre Baranda

  • Joshua Michael Lang

  • Elizabeth R. Plimack

  • Randeep S. Sangha

  • Elisabeth I. Heath

  • Jaime R. Merchan

  • David I. Quinn

  • Sandy Srinivas

  • Matthew I. Milowsky

  • Chunzhang Wu

  • Elaina M Gartner

  • Amal Melhem-Bertrandt

  • Daniel Peter Petrylak

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • University of Michigan, Ann Arbor, MI

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • University of Colorado Cancer Center, Aurora, CO

  • University of Kansas Cancer Center, Fairway, KS

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Fox Chase Cancer Center, Philadelphia, PA

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • University of Miami, Miami, FL

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • UNC Chapel Hill School of Medicine, Chapel Hill, NC

  • Astellas Pharma, Inc., Northbrook, IL

  • Seattle Genetics, Bothell, WA

  • Yale Cancer Center, New Haven, CT

Locations

  • United States

  • Canada

Companies

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Enfortumab vedotin

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02091999

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved